Use of NSAIDs and infection with Helicobacter pylori - What does the rheumatologist need to know?

Rheumatology

Volumn 47, Issue 9, 2008, Pages 1342-1347

  Kiltz, U ^a   Zochling, J ^a   Schmidt, W E ^b   Braun, J ^a  

^a RHEUMAZENTRUM RUHRGEBIET   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

Author keywords

Eradication; Gastroduodenal lesions; Helicobacter pylori; Non steroidal anti inflammatory drugs; Rheumatoid arthritis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; BISMUTH DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR;

ARTICLE; BACTERIUM DETECTION; CLINICAL TRIAL; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; ERADICATION THERAPY; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIGH RISK PATIENT; HUMAN; MEDICAL LITERATURE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK REDUCTION; TREATMENT DURATION; TREATMENT INDICATION;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PEPTIC ULCER; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHEUMATIC DISEASES;

EID: 50849136188     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken123     Document Type: Article

References (43)

1. Suerbaum S, Michetti P. Helicobacter pylori Infection. N Engl J Med 2002;347:1175-86.
2. Parsonnet J, Friedman GD, Vandersteen DP et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991;325:1170-1.
3. You WC, Zhang L, Gail MH et al. Gastric dysplasia and gastric cancer: Helicobacter pylori, serum vitamin C, and other risk factors. J Natl Cancer Inst 2000;92:1607-12.
4. Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
5. International Agency for Research on Cancer. Infection with Helicobacter pylori. In: Schistosomes, liver flukes, and Helicobacter pylori. IARC monographs on the evaluation of carcinogenic risks to humans. Lyon: International Agency for Research on Cancer 1994;61:177-280.
6. Vaira D, Gatta L, Ricci C, Miglioli M. Review article: Diagnosis of Helicobacter pylori infection. Aliment Pharmacol Ther 2002;16(Suppl 1):16-23.
7. Megraud F. Advantages and disadvantages of current diagnosis tests for the detection of Helicobacter pylori. Scand J Gastroenterol Suppl 1996;215:57-62.
8. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998;93:2330-8.
9. Malfertheiner P, Megraud F, O'Morrain C et al. Current concepts in the management of Helicobacter pylori infection - The Maastricht III Consensus Report. Gut 2007;56:772-81.
10. Malfertheiner P, Bayerdorffer E, Diete U et al. The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther 1999;13:703-12.
11. Wong BC, Lam SKL, Wong WM et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China. J Am Med Assoc 2004;291:187-94.
12. Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: A systematic review and meta-analysis. J Natl Cancer Inst 2003;95:1784-91.
13. Chan FKL, Leung WK. Peptic-ulcer disease. Lancet 2002;360:933-41.
14. Fries JF, Murtagh KN, Bennett M, Zatarain E, Lingala B, Bruce B. The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 2004;50:2433-40.
15. Steen KS Nurmohamed MT Visman I et al. Decreasing incidence of symptomatic gastrointestinal ulcers and ulcer complications in patients with rheumatoid arthritis. Ann Rheum Dis 2007 Aug 20; [Epub ahead of print].
16. Chan FKL. NSAID-induced peptic ulcers and Helicobacter pylori infection. Drug Safety 2005;28:287-300.
17. Chan FKL, Sung JJY, Cung SCS et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997;350:975-9.
18. Hawkey CJ, Tulassay Z, Szczepanski L et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Lancet 1998;352:1016-21.
19. Pilotto A, Di Mario F, Franceschi M et al. Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects. Aliment Pharmacol Ther 2000;14:1077-82.
20. Chan FKL, Chung SCS, Suen BY et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001;344:967-73.
21. Chan FKL, To KF, Wu JCY et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: A randomised trial. Lancet 2002;359:9-13.
22. Labenz J, Blum AL, Bolten WW et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: A randomised, double blind, placebo controlled, clinical trial Gut 2002;51:329-35.
23. Lai KC, Lau CS, Ip WY et al. Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: A double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2003;17:799-805.
24. Vergara M, Catalan M, Gisbert JP, Calvet X. Meta-analysis: Role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005;21:1411-8.
25. Labenz J, Peitz U, Kohl H et al. Helicobacter pylori increases the risk of peptic ulcer bleeding: A case-control study. Ital J Gastroenterol Hepatol 1999;31:110-5.
26. Aalykke C, Lauritsen JM, Hallas J, Reinholdt S, Krogfelt K, Lauritsen K. Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: A case-control study. Gastroenterol 1999;116:1305-9.
27. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sainz R. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002;16:779-86.
28. Loeb DS, Talley NJ, Ahlquist DA, Carpenter HA, Zinsmeister AR. Long-term nonsteroidal anti-inflammatory drug use and gastroduodenal injury: The role of Helicobacter pylori infection. Gastroenterol 1992;102:1899-905.
29. Stack WA, Atherton JC, Hawkey GM, Logan RF, Hawkey CJ. Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther 2002;16:497-509.
30. Pilotto A, Leandro G, Di Mario F, Franceschi M, Bozzola L, Valerio G. Role of Helicobacter pylori infection on upper gastrointestinal bleeding in the elderly: A case-control study. Digest Dis Sci 1997;42:586-91.
31. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: A meta-analysis. Lancet 2002;359:14-22.
32. Langman MJ, Weil J, Wainwright P et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:1075-8.
33. Laine L, Bombardier C, Hawkey CJ et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: Results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterol 2002;123:1006-12.
34. Hawkey CJ, Laine L, Simon T et al. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: A multicentre, randomised, double blind study. Gut 2003;52:820-6.
35. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
36. Borer JS, Simon LS. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: Achieving a balance. Arthritis Res Ther 2005;7(Suppl 4): S14-22.
37. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-72.
38. Chan FK, Wong VW, Suen BY et al. Combination of cyclo-oxgenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: A double-blind, randomised trial. Lancet 2007;369:1621-6.
39. Voutilainen M, Sokka T, Juhola M, Farkkila M, Hannonen P. Nonsteroidal anti-inflammatory drug-associated upper gastrointestinal lesions in rheumatoid arthritis patients. Relationships to gastric histology, Helicobacter pylori infection, and other risk factors for peptic ulcer. Scand J Gastroenterol 1998;33:811-6.
40. Taha AS, Sturrock RD, Russel RH. Helicobacter pylori and peptic ulcers in rheumatoid arthritis patients receiving gold, sulfasalazine, and nonsteroidal anti-inflammatory drugs. Am J Gastroenterol 1991;87:1732-5.
41. Chan FKL. Non-steroidal anti-inflammatory drugs and proton-pump inhibitors vs. Cylo-oxygenase-2 selective inhibitors in reducing the risk of recurrent ulcer bleeding in patients with arthritis. Aliment Pharmacol Ther 2005;21(Suppl 1):5-6.
42. Papatheodoridis GV, Archimandritis AJ. Role of Helicobacter pylori eradication in aspirin or non-steroidal anti-inflammatory drug users. World J Gastroenterol 2005;11:3811-6.
43. Dzierzanowska-Fangrat K, Lehours P, Megraud F et al. Diagnosis of Helicobacter pylori infection. Helicobacter 2006;11(Suppl 1):6-13.